Eisai Co., Ltd.
Clinical trials sponsored by Eisai Co., Ltd., explained in plain language.
-
New hope for japanese women with breast cancer: early trial shows promise
Disease control CompletedThis early-stage study tested a new drug called H3B-6545 in 33 Japanese women with a common type of breast cancer (ER-positive, HER2-negative). The main goal was to see if the drug is safe and tolerable, and to find the right dose for Japanese patients. Participants had already t…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:09 UTC
-
Targeted drug shows promise for Tough-to-Treat bile duct cancer
Disease control CompletedThis study tested a drug called E7090 in 63 people with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion) and did not respond to standard chemotherapy. The goal was to see if the drug could shrink tumors. The treatment is not a cure, but aims to control …
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug E7090 shows promise in early trial for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for side effects. In a second part, the drug was also tested in people whose tumor…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:09 UTC